{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:03:17Z","timestamp":1789948997518,"version":"4.0.1"},"reference-count":15,"publisher":"Wiley","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Veterinary Dermatology"],"abstract":"ABSTRACT<\/jats:title>\n \n Background<\/jats:title>\n Oclacitinib is approved for the treatment of canine atopic dermatitis (AD) and pruritus. The conventional administration protocol includes twice\u2010daily oral dosing for 14\u2009days with a subsequent reduction to once\u2010daily administration. This reduction sometimes leads to an increase in pruritus.<\/jats:p>\n <\/jats:sec>\n \n Hypothesis\/Objectives<\/jats:title>\n The aim of this study was to compare the changes in skin lesions and pruritus following a shortened induction versus the conventional protocol for oclacitinib.<\/jats:p>\n <\/jats:sec>\n \n Animals<\/jats:title>\n Forty\u2010five client\u2010owned dogs with AD were randomised into two groups.<\/jats:p>\n <\/jats:sec>\n \n Material and Methods<\/jats:title>\n The conventional protocol group (CP) received oclacitinib tablets at 0.4\u20130.6\u2009mg\/kg twice\u2010daily for 14\u2009days, then once\u2010daily for 7\u2009days. In the shortened induction protocol group (SIP), oclacitinib was administered twice\u2010daily for 6\u2009days, then once\u2010daily for 15\u2009days. Pruritus was assessed daily by the owners using a pruritus Visual Analog Scale (PVAS). Lesions were scored with the Canine Atopic Dermatitis Lesion Index (CADLI) at Day (D) 0 and D21.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Data from 40 dogs were available. Mean CADLI scores decreased from 13.4 to 8 in the CP group (\n p<\/jats:italic>\n \u2009=\u20090.12) and from 12.9 to 6.9 in the SIP group (\n p<\/jats:italic>\n \u2009=\u20090.01), respectively. Mean pruritus scores decreased from 6.4 to 2.1 and from 5.7 to 1.9, respectively (\n p<\/jats:italic>\n \u2009<\u20090.0001 each). No between\u2010group differences were observed. An increase in pruritus following dose reduction was seen in two dogs (CP) and one dog (SIP).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Clinical Relevance<\/jats:title>\n The SIP was not significantly different to the CP with respect to improvement in lesion severity or pruritus.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/vde.70127","type":"journal-article","created":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:44:33Z","timestamp":1789947873000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of Two Induction Protocols for Oclacitinib in Dogs"],"prefix":"10.1111","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7601-6409","authenticated-orcid":false,"given":"Paulina J. C.","family":"Popp","sequence":"first","affiliation":[{"name":"Small Animal Clinic LMU Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5835-5910","authenticated-orcid":false,"given":"Ralf S.","family":"Mueller","sequence":"additional","affiliation":[{"name":"Small Animal Clinic LMU Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Widorn","sequence":"additional","affiliation":[{"name":"Small Animal Clinic LMU Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Udraite\u2010Vovk","sequence":"additional","affiliation":[{"name":"Small Animal Clinic LMU Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4935-1042","authenticated-orcid":false,"given":"Ulrike","family":"Mueller","sequence":"additional","affiliation":[{"name":"Small Animal Clinic LMU Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8068-2288","authenticated-orcid":false,"given":"Tamara","family":"Weitzer","sequence":"additional","affiliation":[{"name":"Small Animal Clinic LMU Munich Munich Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/vde.12088","article-title":"A Blinded, Randomized, Placebo\u2010Controlled Trial of the Efficacy and Safety of the Janus Kinase Inhibitor Oclacitinib (Apoquel) in Client\u2010Owned Dogs With Atopic Dermatitis","volume":"24","author":"Cosgrove S. B.","year":"2013","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_3_1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL) is a Novel Janus Kinase Inhibitor With Activity Against Cytokines Involved in Allergy","volume":"37","author":"Gonzales A. J.","year":"2014","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","DOI":"10.1111\/vde.12047","article-title":"Efficacy and Safety of Oclacitinib for the Control of Pruritus and Associated Skin Lesions in Dogs With Canine Allergic Dermatitis","volume":"24","author":"Cosgrove S. B.","year":"2013","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_5_1","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/vde.12194","article-title":"Long\u2010Term Compassionate Use of Oclacitinib in Dogs With Atopic and Allergic Skin Disease: Safety, Efficacy and Quality of Life","volume":"26","author":"Cosgrove S. B.","year":"2015","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_6_1","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/vde.12186","article-title":"A Blinded, Randomized Clinical Trial Comparing the Efficacy and Safety of Oclacitinib and Ciclosporin for the Control of Atopic Dermatitis in Client\u2010Owned Dogs","volume":"26","author":"Little P. R.","year":"2015","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_7_1","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/vde.12166","article-title":"Efficacy of Oclacitinib (Apoquel) Compared With Prednisolone for the Control of Pruritus and Clinical Signs Associated With Allergic Dermatitis in Client\u2010Owned Dogs in Australia","volume":"25","author":"Gadeyne C.","year":"2014","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_8_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/vde.13134","article-title":"A Randomised Controlled Trial Testing the Rebound\u2010Preventing Benefit of Four Days of Prednisolone During the Induction of Oclacitinib Therapy in Dogs With Atopic Dermatitis","volume":"34","author":"Olivry T.","year":"2023","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_9_1","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ejphar.2016.11.020","article-title":"Demonstration of Rebound Phenomenon Following Abrupt Withdrawal of the JAK1 Inhibitor Oclacitinib","volume":"794","author":"Fukuyama T.","year":"2017","journal-title":"European Journal of Pharmacology"},{"key":"e_1_2_11_10_1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/vde.13193","article-title":"A Randomised, Double\u2010Blinded, Controlled Trial to Determine the Efficacy of Combined Therapy of Oclacitinib and Marine Oil Extract PCSO\u2010524 in Dogs With Atopic Dermatitis","volume":"34","author":"Nishiyama T.","year":"2023","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_11_1","doi-asserted-by":"crossref","first-page":"255","DOI":"10.5326\/JAAHA-MS-7396","article-title":"2023 AAHA Management of Allergic Skin Diseases in Dogs and Cats Guidelines","volume":"59","author":"Miller J.","year":"2023","journal-title":"Journal of the American Animal Hospital Association"},{"key":"e_1_2_11_12_1","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-3164.2007.00616.x","article-title":"Development of an Owner\u2010Assessed Scale to Measure the Severity of Pruritus in Dogs","volume":"18","author":"Hill P. B.","year":"2007","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_13_1","article-title":"Development and Validation of the Canine Atopic Dermatitis Lesion Index, a Scale for the Rapid Scoring of Lesion Severity in Canine Atopic Dermatitis","volume":"2","author":"Plant J. D.","year":"2012","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_14_1","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/j.1365-3164.2008.00728.x","article-title":"Further Validation of a Pruritus Severity Scale for Use in Dogs","volume":"20","author":"Rybnicek J.","year":"2009","journal-title":"Veterinary Dermatology"},{"key":"e_1_2_11_15_1","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/jvp.12087","article-title":"The Pharmacokinetics of Oclacitinib Maleate, a Janus Kinase Inhibitor, in the Dog","volume":"37","author":"Collard W. T.","year":"2014","journal-title":"Journal of Veterinary Pharmacology and Therapeutics"},{"issue":"1","key":"e_1_2_11_16_1","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.2460\/javma.22.12.0570","article-title":"Oclacitinib 10\u2009Years Later: Lessons Learned and Directions for the Future","volume":"261","author":"Marsella R.","year":"2023","journal-title":"Journal of the American Veterinary Medical Association"}],"container-title":["Veterinary Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.70127","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/vde.70127","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/vde.70127","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T23:44:40Z","timestamp":1789947880000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/vde.70127"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":15,"alternative-id":["10.1111\/vde.70127"],"URL":"https:\/\/doi.org\/10.1111\/vde.70127","archive":["Portico"],"relation":{},"ISSN":["0959-4493","1365-3164"],"issn-type":[{"value":"0959-4493","type":"print"},{"value":"1365-3164","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"assertion":[{"value":"2026-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-20","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"vde.70127"}}